Vemurafenib sensitivity skin reaction after ipilimumab

New England Journal of Medicine

Volumn 366, Issue 9, 2012, Pages 866-868

  Harding, James J ^a   Pulitzer, Melissa ^a   Chapman, Paul B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; IPILIMUMAB; VEMURAFENIB;

ADULT; AGED; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL ARTICLE; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG WITHDRAWAL; EDEMA; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOLOGY; LETTER; MACULOPAPULAR RASH; MELANOMA; METASTASIS; PRIORITY JOURNAL; PRURITUS; SKIN ALLERGY; SKIN BIOPSY;

EID: 84857871490     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1114329     Document Type: Letter

References (4)

1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23. [Erratum, N Engl J Med 2010;363:1290.]
2. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26.
3. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
4. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-14.